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ABSTRACT
The BOG25 family proteins, BOG25 and 7a5, contain domains of the EH- 
Network family of endocytosis, intracellular sorting and cell fate determination proteins 
as well as a C-terminal death domain that may play an important role in apoptosis. No 
other known proteins contain the same domain combinations which makes this family 
unique. The normal physiological roles of the BOG25 family of proteins are currently 
unknown, and this is the first study of the possible role of BOG25 and 7a5 in cancer. 
Additionally, this study is the first to confirm the transcription of mRNA for 7a5, the 
putative protein identified as similar to BOG25 by the Human Genome Project. Three 
cDNA sequences were subcloned, sequenced and aligned with 100% identity, the 
predicted coding region of 7a5 from the genomic sequence submitted by the Human 
Genome Project.
The hypothesis of this study is that BOG25 and 7a5 proteins play an important 
role in the cancer phenotype, and therefore, will have a substantial differential expression 
between the cancer cell lines and/or between the cancer and normal cell lines. Western 
blot, subcellular fractionation and Reverse Transcription-Polymerase Chain Reaction 
(RT-PCR) were used to analyze three sets of cell lines: bladder, prostate and breast. The 
most advanced cancerous bladder cell line, HTB 5, expressed a very high level of 7a5 
protein, while the most differentiated cancer cell line, HTB 2, expressed the lowest level. 
Conversely, BOG25 and 7a5 proteins in prostate cell lines showed no major difference
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between the cell lines. However, the breast cancer cell line, Hs578T expressed BOG25 
protein at a high level compared to all of the other breast cell lines. Based on these 
results, the breast cell lines were further characterized using subcellular fractionation and 
RT-PCR to examine mRNA and corresponding protein levels. Subcellular fractionation 
revealed BOG25 expression at approximately a 1:1 ratio of PNF to NF in all breast cell 
lines including Hs578T cells while 7a5 was expressed at higher levels in the PNF than 
NF in all cell lines. No major alteration in subcellular localization was observed for 
either BOG25 or 7a5 in the Hs578T cell line compared to the other breast cell lines. RT- 
PCR of triplicate total RNA samples from breast cells showed that Hs578T expressed a 
very high level of BOG25 mRNA compared to all other cell lines. Corresponding triplet 
lysates analyzed for BOG25 and 7a5 protein expression showed that protein levels were 
comparable to the mRNA levels where all cell lines expressed BOG25 at a much lower 
level than Hs578T. Only one sample showed a correctly sized 7a5 mRNA band for the 
MDA cell line. All samples for the other cell lines expressed similar 7a5 mRNA levels. 
Triplicate 7a5 protein data showed subtle differences among cell lines that were 
comparable to the mRNA data. The unique domain combinations and the highest 
expression in the most advanced cancer are persuasive reasons for BOG25 and 7a5 to be 




BOG25 And Consensus Sequences
BOG25 is a novel 120kD protein that was first identified, sequenced, and 
characterized in human corneal fibroblasts (Dunlevy el al., 1999). This research showed 
that BOG25 is encoded on human chromosome 2q37. l-q37.2 by fluorescence in situ 
hybridization analysis. The official gene name for BOG25 is SH3-domain-Binding 
Protein 4 (SH3BP4) (Dunlevy et a l , 1999), but will remain named BOG25 in this thesis. 
Encoded within the 963 amino acid open reading frame of BOG25, is a unique 
combination of consensus sequences and domains that no other known protein contains 
(Figure 1). The consensus sequences include: an SH3 domain, a P-X-X-P sequence, 
three N-P-F motifs, a bipartite nuclear targeting sequence, tyrosine phosphorylation 
sequence (Dunlevy et al., 1999) and a death domain. BOG25 contain domains of the EH- 
Network family of endocytosis, intracellular signal transduction and cell fate 
determination proteins and to the death domain family of proteins.
Src-Homology 3 (SH3) domains are involved in protein-protein interactions that 
include: interacting proteins with the cytoskeleton, interacting with proteins involved in 
endocytosis, including clathrin vesicle formation (Simpson et al., 1999), subcellular 
localization of signaling proteins, organization of protein complexes, and binding 















Figure 1: Consensus sequences of BOG25. The consensus regions within BOG25 
include SH3 domain, N-P-F repeats, P-X-X-P sequence, bipartite nuclear targeting 
sequence, tyrosine phosphorylation sequence, and death domain. Open box represents 
the 963 amino acid open reading frame, and the closed boxes are the 335-nucleotide 5’ 
and 1920-nucleotide 3’ untranslated regions.
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Analysis of the SH3 binding site of the protein Abl (3BP2) showed the SH3 domain 
binds to the amino acid sequence P-X- X-P (where P is proline, and X is any amino acid) 
within a ten-amino acid proline-rich region (Ren etal., 1993). SH3 domain analysis of 
Abl and Src indicates there are numerous different SH3 domains, and there are many 
different binding sites/sequences on target proteins (Ren etal., 1993). SH3 domains 
differentially bind the various consensus sequences causing each SH3 domain-containing 
protein to require a specific target protein (Ren et al., 1993) and hence a different cellular 
response. SH3 domains and P-X-X-P binding sites are also found on many EH-Network 
proteins (Santolini etal., 1999). Epsl5 and Epsl5R each contain three SH3 domains, 
while short intersectin and its related protein long intersectin both contain five SH3 
domains each (Santolini et al., 1999).
Proteins that contain an EH domain or the EH domain binding sequence of N-P-F 
belong to the EH-network (Confalonieri and Di Fiore, 2002). The EH-network (for 
Epsl 5 Homology) is important in protein-protein binding in cellular functions such as 
endocytosis of the epidermal growth factor receptor (EGFR) (Confalonieri etal., 2000) , 
intracellular signal transduction (Santolini et al., 1999) and cell fate determination 
(Confalonieri and Di Fiore, 2002). The EH domain is 66 amino acids in length and was 
first identified in Epsl 5 (Wong et al., 1995), a substrate for the tyrosine kinase activity of 
epidermal growth factor receptor (EGFR) (Fazioli et a l, 1993). The N-P-F (Asn- Pro- 
Phe) amino acid sequence has been identified as a binding site for EH (E psl5 Homology) 
domains (Mayer, 1999) and is found in EH-binding proteins (Santolini et al., 1999).
Many EH-domain containing proteins and EH-binding proteins are found in pairs such as 
E p sl5 and Epsl5R, NUMB and NUMBR, intersectin 1 and 2 and EH-binding proteins
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Epsin 1 and 2 (Santolini etal., 1999). Epsl5 plays an important role in clathrin-mediated 
endocytosis. Intersectin, Epsl5 and Epsl5R and an EH binding protein, Epsin, are 
regulatory and assembly proteins for clathrin coat assembly and vesicle invagination 
(Santolini etal., 1999). The interrelationship of EH-Network proteins and SH3 domains 
shows that endocytosis is a very complex scaffolding process.
The bipartite nuclear targeting sequence is a known sequence for targeting 
proteins to the nucleus (Dingwall and Larskey, 1991). The targeting sequence consists of 
two basic amino acids, any ten amino acids, followed by a cluster of five amino acids of 
which three must be basic (Dingwall and Larskey, 1991). Nuclear proteins that include 
transcription factors, DNA polymerases and androgen and estrogen steroid hormone 
receptors all contain the bipartite nuclear targeting sequence. Nonnuclear proteins such 
as Epsl5R also contains the nuclear targeting sequence, although Epsl5R has also been 
reported in the nucleus (Coda etal., 1998).
Tyrosine phosphorylation sequences are sequences within proteins that are 
phosphorylated by receptor tyrosine kinases (Alberts et al., 2002). Receptor tyrosine 
kinases are located on the plasma membrane and include EGFR. Upon binding of an 
extracellular ligand (e.g. epidermal growth factor, fibroblast growth factor or insulin), 
receptor tyrosine kinases dimerize, and phosphorylate the other receptor proteins and 
many other proteins that contain a tyrosine phosphorylation sequence to transduce the 
signal and elicit a specific response (Alberts et al., 2002). Responses of tyrosine kinases 
include cell proliferation, growth and survival (Alberts et al., 2002). The EH-domain 
containing proteins Epsl5 and Epsl5R are both phosphorylated by the EGFR (Fazioli et 
al., 1993; Coda etal., 1998).
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The death domain is a protein-protein interaction domain about 80 amino acids in 
length found in the C-terminus in cytosolic regions of proteins involved in the apoptotic 
protease cascade (Tartaglia et al., 1993). These proteins include receptors found in the 
Tumor Necrosis Factor (TNT) receptor family: TNFReceptor-1 andFas/Apol (Feinstein 
et a l, 1995; Reed, 2003). Adaptor, or docking proteins, associated with the TNF receptor 
family also contain death domains and include Fas-Associated Death Domain/Mediator 
Of Receptor-Induced Toxicity 1 (FADD/MORT1) and TNFR1-Associated Death Domain 
(TRADD) (Boldin et a l, 1995; Hsu et al., 1995). Upon FasL ligand binding, the Fas 
receptor aggregates and binds FADD by the death domain on each protein (Lambert et 
al., 2003). FADD activates the caspase cascade leading to apoptotic cell death.
The domain combinations within BOG25 have focused recent studies on the 
determination of the subcellular localization of BOG25 using fusion proteins. The 
BOG25 immune IgY antibody has been shown to recognize two specific 120 kD and 100 
kD bands on a Western blot, and bands for BOG25 fusion proteins that migrated correct 
to size of the 120 kD band (Khanobdee et al ., 2003 Abs). Endogenous BOG25 protein 
was found to localize to membrane and nuclear fractions of human retinal pigment 
epithelial, ARPE-19, and COS-7 cells (Khanobdee K et al., 2003 Abs). Subcellular 
fractionation studies determined BOG25 fusion proteins localized to the plasma 
membrane and nuclear periphery. Confocal microscopy also showed a localization 
pattern to the plasma membrane and nuclear periphery with altered cell morphology in 
many but not all cells. ARPE-19 cells over-expressing full-length BOG25 fusion 
proteins in the pEGFP and c-myc-tagged pCMV-Tag3 vectors show an increase in the 
percent of cells with condensed nuclei compared to non-expressing neighboring cells and
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cells containing control vectors. Additionally, an N-terminal truncated BOG25 construct 
was found to be more effective than full length constructs at inducing cell rounding and 
nuclear condensation (Koppelman et al., 2003 Abs; Dunlevy 2004 Abs).
7a5
The Human Genome Project recently identified a gene on chromosome 7 p l5.3 
that was homologous to BOG25 and named the putative protein 7a5. 7a5 is a 105 kD 
protein that is believed to be the lower 100 kD band on the Western blot; it is exactly 
15kD smaller than BOG25 and its amino acid sequence is highly homologous to BOG25, 
having 60% identity and similarity. The consensus sequences and domains of the 7a5 
protein are similar to those of BOG25: two N-P-F EH binding motifs, one P-X-X-P SH3 
binding motif, three tyrosine phosphorylation sites and one death domain that has a 75% 
identity and similarity to the death domain of BOG25 (Figure 2). The 7a5 protein is 
currently completely uncharacterized as nothing is known or has been published about it.
Cancer
Cancer is the second leading cause of death in the United States. It is well known 
that cancer alters normal cell physiology to form abnormal cells that promote growth and 
resist apoptosis. Abnormal cells include cells that have lost their ability to repair 
damaged DNA, correct replication errors, maintain chromosome integrity and/or have 
accumulated multiple mutations (Alberts et al., 2002). Abnormal cells that exhibit 
metaplasia and neoplastic hyperplasia will create a tumor or neoplasm (Goodman and 





Figure 2: Consensus sequences of 7a5. The consensus regions within 7a5 include 2 N-P- 
F sequences, a P-X-X-P sequence, 3 tyrosine phosphorylation sequences, and a death 
domain. The open box represents the 816 amino acid open reading frame for 7a5.
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Cancer is the uncontrolled growth and proliferation of tumors in any organ system 
(Goodman and Kelly Snyder, 2003). Malignant tumors can be classified by cell type, or 
named by the tissue of origin (Goodman and Kelly Snyder, 2003). Carcinoma is a cancer 
originating from epithelial cells. Adenocarcinoma is a malignant tumor originating from 
the lining/epithelial cells of organs or glands. Carcinosarcoma is a malignant tumor 
originating from epithelial cells and connective tissue such as bone, cartilage and fat. 
Tumors assume an undifferentiated phenotype, become immune evasive and apoptosis 
resistant and often rearrange the extracellular matrix to then invade the surrounding 
connective tissue (Goodman and Kelly Snyder, 2003). Jacks and Weinberg (2002) have 
presented that the basement membrane of epithelial cells acts as a barrier between 
epithelial cells and the surrounding stroma to restrict passage from the reservoir of 
molecules, such as growth factors, contained within the basement membrane. Tumor 
cells can secrete different compositions of extracellular matrix to gain access to the 
growth factors in order to maintain survival (Jacks and Weinberg, 2002). Once 
malignant tumors have invaded surrounding tissue, most often they metastasize from the 
primary tumor to specific regions of the body through blood vessels created by 
angiogenesis, or through the lymph system (Goodman and Kelly Snyder, 2003). 
Metastatic cells can accumulate within the lymph nodes or travel through the lymph 
nodes to distant organs.
There are several ways to classify, or stage, cancer. Currently, the most powerful 
prognostic factor is considered the stage of the cancer (Hillegas, 2003). The TNM 
(Tumor,Nodes,Metastasis) classification system is a clinical staging based on biopsies 
and diagnostic tests (American Joint Committee on Cancer, 2002). TNM stands for size
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of tumor, spread to regional lymph nodes, and presence or absence of metastasis. Type 
of and histological grade of a tumor and estrogen and progesterone receptor status, in 
breast and prostate cancer respectively, are also utilized in staging (Hillegas, 2003). 
Histologic grade depends on the number of nuclei and aneuploidy (Hillegas, 2003). The 
higher the grade is, the more aggressive the cancer, and the poorer the prognosis.
Prognosis is the prediction of a probable course or outcome of a disease. Isolation 
of molecular markers such as genes, RNA and proteins from biopsy serum, urine or 
lymph fluid are used as cancer prognostic markers (Sidransky, 2002). Examining DNA 
mutations is valuable in monitoring metastasis and determining prognosis, while RNA 
analysis is key for expression level changes or point mutations in genes and analysis of 
proteins is important for differential localization or changes in protein expression 
(Sidransky, 2002). Although the stage of the cancer is considered the most powerful 
prognostic factor, TNM is utilized only after a cancer has progressed undetected for 
possibly years within the body, with the probability that metastasis has already occurred. 
Other prognostic markers are needed to identify cancer at earlier stages, monitor disease 
progression and determine response to therapy (Sidransky, 2002). For example, it is well 
known that early stage breast cancer patients already have microscopic metastases at 
diagnosis (Esteva and Hortobagyi, 2004). However, adjuvant systemic therapies are 
potentially toxic to those patients who do not need that aggressive of a therapy. Early 




Apoptosis, or programmed cell death, is morphologically characterized by 
chromatin condensation, nuclear fragmentation, plasma membrane blebbing and cell 
shrinkage (Alberts et al., 2002). The blebs and apoptotic cells are phagocytosed by 
macrophages or neighboring parenchymal cells (Alberts et al., 2002). Necrosis, on the 
other hand, is death by cell lysis causing inflammation. The cell becomes swelled, the 
plasma membrane is disrupted and the cell is lysed releasing cytoplasmic contents 
causing disruption to surrounding tissues, and usually a damaging inflammatory response 
(Alberts eta l., 2002).
Two well characterized pathways of apoptosis induction include the extrinsic 
pathway and the intrinsic pathway (Boatright and Salvesen, 2003; Maag e ta l,  2003).
The extrinsic pathway is initiated upon ligand binding to receptors, such as TNFR-1 and 
Fas, that contain a death domain (Reed, 2000). The death domain is found in both 
adaptor proteins and receptors, and is important for cell death by being utilized as a 
docking protein to recruit signaling proteins to the receptor (Wallach et al., 1999). The 
death domain of FADD, an adaptor protein, utilizes its death domain to bind another 
FADD, and/or Fas and is required for apoptosis to occur (Boldin etal., 1995; Chinnaiyan 
et al., 1995; Gomez-Angelats and Cidlowski, 2003; Reed, 2000). By its death effector 
domain, FADD links the Fas receptor to procaspase-8 monomers to allow dimer 
formation and activation of caspase-8 (Boatright and Salvesen, 2003). This signaling 
mechanism of Fas, FADD and caspase-8 is also known as the death-inducing signal 
complex (Gomez-Angelats and Cidlowski, 2003).
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The intrinsic pathway involves the unbalanced ratio of anti- and pro-apoptotic 
Bcl-2 family proteins favoring the pro-apoptotic family members (Reed, 2000). Caspase- 
8 can cleave the pro-apoptotic Bid protein in the cytoplasm where Bid then translocates 
to the mitochondria to release cytochrome c (Luo et a/., 1998). A caspase activating 
protein Apaf-1 located in the cytosol that hydrolyzes ATP binds the released cytochrome- 
c (Zou etal., 1999). This complex, known as the apoptosome, binds, orients, processes 
and activates procaspase-9 (Zou et a l, 1999). The intrinsic pathway eliminates cells 
damaged from ionizing radiation and mitochondrial damage (Boatright & Salvesen, 
2003).
Caspases are cysteine proteases that exist as zymogens until they are cleaved into 
their active state. There are both initiator and effector caspases (Salveson and Dixit, 
1997). The large N-terminal prodomain of initiator caspases interacts with proteins that 
initiate their activation (Reed, 2003). Initiator caspases, including caspase-8 and caspase- 
9, then cleave off the short N-terminal prodomains of effector caspases that include 
caspase-3 and caspase-7 (Boatright and Salvesen, 2003). Effector caspases then cleave 
DNA repair proteins, protein kinases, cytoskeletal and nuclear matrix proteins that will 
cause DNA fragmentation, cell blebbing and membrane shrinking (Reed, 2000). 
Phagocytosis of the blebs and the cells can then occur by macrophages or neighboring 
parenchymal cells (Alberts etal., 2002).
Cancer results in acquired resistance to apoptosis that can lead to abnormal cell 
longevity, a loss of dependence on exogenous growth factors, resistance to the immune 
system, protection from oxidative stress and the allowance for genetic mutation 
accumulation (Reed, 2003). Still, another viewpoint maintains that cells containing
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defects in DNA repair, chromosome segregation and apoptosis allow unstable abnormal 
cell viability/survival that can ultimately lead to cancer and chemoresistance (Reed,
2003).
EH-Network and Cancer
Epidermal growth factor receptor (EGFR) requires phosphorylation of Epsl5 for 
its recruitment by coated pits (Di Fiore and De Camilli, 2001; Di Fiore and Gill, 1999). 
Overexpression of the EGFR substrate Epsl5 has been shown to transform NIH 3T3 
fibroblast cells that then have the ability to grow in soft agar (Fazioli et al., 1993). The 
EpsJ5 gene has been involved in translocations in acute lymphoblastic and myeloid 
leukemias (Salcini et al., 1999). The EGFR plays an important role in neoplastic cell 
proliferation, angiogenesis and metastatic spread (Dancey, 2004). The overexpression of 
EGFR is the most frequently reported abnormality in non-small cell lung cancer with 
very poor survival prognosis with treatment (Dancey, 2004). However, trial studies show 
mixed results in the effectiveness of treating EGFR in non-small cell lung cancer 
(Dancey, 2004). Cancers often mutationally change the outcome of transduction of 
signaling pathways to deregulate cell growth, differentiation and apoptosis (Martin, 2003) 
in order to survive. Tumors can also escape inhibition of one signaling pathway by 
activating another signaling pathway (Martin, 2003). Since the EGFR is not commonly 
mutated in cancers (Dancey, 2004), utilizing other signaling pathways is a possible 
method of escape from aggressive therapies.
The unique combination of consensus sequences and domain homologies that 
include the SH3 domain, N-P-F EH binding sequence, and death domain, indicate that
12
BOG25 and 7a5 are important in protein-protein binding that may bridge intracellular 
sorting and apoptosis and therefore, may be important to the cancer phenotype.
Bladder Cancer
The histology of the bladder is comprised by the urothelium (transitional 
epithelium) at the lumen, surrounded by connective tissue (lamina propria), encircled by 
two layers of smooth muscle (muscularis propria), and adipose tissue (adventitia). 
Invasive urothelial tumors are cancers that have spread into the muscularis propria. 
Bladder cancer cell lines used in this study that were invasive are HTB1, HTB 5, and 
CRL-1472 (Masters et al., 1986). The HTB 2 cell line is a papillary low-grade 
transitional cell carcinoma (Masters et al., 1986). HTB1 is an invasive, high grade 
transitional cell carcinoma that has spread to the adventitia (Masters et al., 1986) while 
HTB 5 is an invasive, metastatic high grade transitional cell carcinoma (Masters et al, 
1986), and CRL-1472 is an invasive transitional cell carcinoma (Masters et al., 1986). 
Papillary urothelial carcinoma consists of finger-like projections of urothelium into the 
lumen of the bladder.
The total estimated bladder cancer cases in the United States for 2004 are 60,240 
and the total estimated deaths are 12,710 in 2004 (Ries et al., 2001). Bladder cancer is 
the fourth cause of cancer in men, and ninety to ninety-eight percent of bladder cancers 
are transitional cell carcinomas (Boissannault, 2003). Mutations in the tumor suppressor 
genes, p53 or Rb are considered important in the development of bladder cancer. Current 
prognostic markers utilized in bladder cancer include TP53 gene mutations, 
microsatelline alterations, cytokeratin and survivin RNA, survivin protein, and DNA
13
hypermethylation of certain E-cadherins and death-associated protein kinase (Sidransky, 
2002).
Prostate Cancer
The prostate is an important male gland producing the protective and nourishing 
seminal fluid for sperm. The gland is only about the size of a walnut and encompasses 
the urethra just below the bladder. Prostate cancer is the second cause of cancer-related 
death in men (Boissannault and Goodman, 2003). Most prostate cancers grow slowly, 
many of which are undetected throughout the lifetime of a man diagnosed with prostate 
cancer. Many prostate cancers are found confined within the prostate or from invasion of 
the seminal vesicles and urinary bladder (Boissannault and Goodman, 2003; Wilson and 
Hillegas, 2003). Binding of the androgen testosterone, that is secreted primarily by the 
testes, or the more active hormone 5a-dihydrotestosterone to an androgen receptor causes 
the complex to enter the nucleus and activate DNA for cell growth, survival and an 
elevated level of prostate specific antigen (Feldman and Feldman, 2001). Prostate tumor 
growth is originally androgen dependent, however, regression of cancer after androgen 
ablation therapy causes androgen independent prostate cancer to form, which is a more 
lethal form of prostate cancer (Feldman and Feldman, 2001).
The total estimated prostate cancer cases in the United States for 2004 are 
230,110 and the total estimated deaths are 29,900 (Ries et al., 2001). About 98% of 
prostate cancers are adenocarcinomas that begin in the periphery and then infiltrate the 
gland (Boissannault and Goodman, 2003; Wilson and Hillegas, 2003). Cell lines used in 
this study that were adenocarcinomas were LNCaP the androgen responsive cell line 
(Webber et al., 1997), and the androgen independent cell lines DU-145 and PC-3
14
(Webber et al., 1997). Current prognostic markers utilized for prostate cancer include 
RNA and protein for the prostate specific antigen (Sidransky, 2002).
Breast Cancer
Normal anatomy of the breast consists of 15-25 lobes of glandular tissue, with 
fibrous strands of connective tissue (stroma) separating the lobes as well as separating the 
breast from the chest wall (Hillegas, 2003). Adipose tissue surrounds each glandular lobe 
within the confines of the connective tissue (Hillegas, 2003). Estrogen is necessary for 
proliferation of mammary cells and is believed to promote the proliferation of 
transformed cells (Goodman, 2003b). Infiltrating ductal carcinoma is the most common 
infiltrating breast cancer, which invades the stroma beyond the duct and can potentially 
metastasize (Hillegas, 2003). Breast metastases occur through mammary ducts and 
through internal mammary, axillary and supraclavicular lymph nodes (Hillegas, 2003). 
About 80% of breast cancers are adenocarcinomas originating in the ducts or lobules of 
the breast (Goodman, 2003b). The adenocarcinoma cell lines used in this study are 
MDA-MB-231 (MDA), MCF-7, and T-47D (Burdall et al., 2003). Carcinosarcoma is 
rare for breast cancers, and the Hs578T cell line used in this study is a carcinosarcoma 
(Hackett et al., 1977). These cell lines were collected from pleural effusions, or drainage 
of lymph fluid from metastases to the surrounding lymph nodes (Burdall et al., 2003; 
Hackett et al., 1977). MDA and Hs578T are estrogen receptor negative cell lines and 
MCF-7 and T-47D are estrogen receptor positive cell lines (Hackett et al., 1977; Burdall 
et al., 2003).
The total estimated breast cancer cases for women in the United States for 2004 
are 215,990 (Ries et al., 2004). Breast cancer is the second most common cancer for
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women, and is the leading cause of cancer deaths (Hillegas, 2003). Although diagnosing 
whether a breast lesion is benign, pre-cancerous or cancerous has become more straight­
forward, determining the prognosis for patients with cancerous lesions is not well 
defined. Often cancer patients are treated with aggressive chemotherapy and radiation 
when many do not need such aggressive treatment simply due to the lack of reliable 
prognostic markers. Therefore, many proteins are screened for expression relative to 
patient outcome in attempts to identify good prognostic markers. The EGF receptors 
(EGFR, ErbB2, ErbB3) are involved in mammary gland development and are over­
expressed in breast cancer (Stern, 2000). The potential prognostic marker gene in breast 
cancer, Epsl5, is down-regulated in patients with short survival (Amatschek etal., 2004). 
DNA microsatellite alterations, RNA cytokeratins, and hypermethylation of the BRCA1 
gene are also prognostic markers (Sidransky, 2002). Estrogen receptor positive 
expression in breast cancers is an important initial determinant of prognosis; its 
expression determines the amount and type (usually aggressive) of therapy a patient will 
receive. Overexpression of the estrogen receptor ER a is an excellent initial predictive 
factor, although it has been positively correlated with a good prognostic outcome 
diminishing its status as an independent prognostic marker (Esteva and Hortobagyi, 
2004). While systemic therapy improves early ER positive breast cancer survival of 
those patients (Esteva and Hortobagyi, 2004), the therapy can be toxic to those patients 
who do not need the aggressive approach in treating their cancer.
Statement o f Hypothesis
BOG25 and 7a5 contain a unique domain combination of the EH-Network family 
of endocytosis, intracellular signal transduction and cell fate determination proteins and
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of the death domain family of proteins. All domains except the death domain are 
contained within the EH-Network family of proteins.
Since cancers are known to promote growth and resist apoptosis, the working 
hypothesis for the current study is that the BOG25 family of proteins are important to the 
cancer phenotype and therefore, will exhibit a substantial differential expression between 
some cancer cell lines and/or normal cell lines if they are important to the cancer 
phenotype.
To test this hypothesis, bladder, prostate, and breast cell lines were screened for 
BOG25 and 7a5 protein expression and based on preliminary results, breast cell lines 
were examined further for determination of subcellular localization and message levels. 
Several research questions were addressed including: Are there differences in protein 
expression and/or message levels between normal and cancerous cells or between 
cancerous cell lines? Is there a subcellular localization re-distribution of BOG25 proteins 
between normal and cancerous cells or between cancerous cell lines? These fundamental 
questions are scientifically important as changes in intracellular localization, message 
levels and/or protein levels of BOG25 and 7a5 proteins may give important insight into 




To answer the hypothesis-driven questions regarding differences in protein 
expression, message levels and the subcellular localizations for BOG25 and 7a5, multiple 
techniques were used. Cell culture was critical for both protein and message analyses. 
Protein levels were determined using Western blot analyses, which included 
determination of total protein concentrations for cell lysates. The subcellular 
fractionation technique was chosen based on studies in the lab, and is the NE-PER 
protocol from Pierce. RT-PCR was critical in confirming the predicted 7a5 cDNA 
sequence that involved subcloning and sequencing portions of amplified 7a5. RT-PCR 
was also important for determining message levels from total RNA isolated from the cell 
lines and were compared to corresponding protein levels. Primers for RT-PCR were 
engineered to specifically amplify BOG25 or 7a5 without cross-reacting with these 
similar sequences. All PCR products were visualized on agarose gels.
Cell Culture
Cell lines were obtained from Dr. Don Sens (Professor of Surgery, UND School 
of Medicine and Health Sciences Grand Forks, ND). Breast cell lines include: normal 
breast epithelial cells: MCF-10; estrogen receptor negative (ER') cells: MDA-MB-231 
and Hs578T; and estrogen receptor positive (ER^) cells: MCF-7 and T-47D. Bladder cell 
lines include: normal bladder epithelial cells: UROtsa; three levels of transitional cell
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carcinoma cells: high-grade HTB 1, papillary low-grade HTB 2, and metastatic high- 
grade HTB 5; and carcinoma cells: CRL-1472. Prostate cell lines include normal prostate 
epithelial cells: RWPE; androgen responsive cells: LNCaP; and androgen independent 
cells: DU-145 and PC-3. Cells were maintained in growth medium until confluence in T- 
75 or T-25 flasks and were usually harvested 24 hours after the last medium change.
Total Cell Lysates
Total cell lysate controls were collected by rinsing cells with phenol red free 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (Ham) (1:1) (Gibco, 
Carlsbad, CA or Hyclone Laboratories, Logan, UT), then lysing the cells with 2%
Sodium Dodecyl Sulfate (SDS) in Phosphate Buffered Saline (PBS) with 3mM MgCh, 
ImMEGTA, lOmMNa pyrophosphate, lOmM orthovanadate, 50mMNaF and Complete 
EDTA protease inhibitors (Roche Applied Science, Indianapolis, IN). Lysates were 
sonicated briefly, ~3-5 sec, and stored at -20°C.
Determination o f Total Protein Concentration 
Total protein concentration was determined using the BCA assay (Pierce, 
Rockford, IL). Briefly, a range of bovine serum, albumin (BSA) standards, Opg to 
2000pg, were prepared, and cupric-sulfate buffer reagent was added to cell lysates, cell 
fractions and standards. All samples were incubated at 37°C for 30 min. Protein 
concentration was determined for some samples under an enhanced protocol: BSA 
standard range was Opg -300pg and samples and standards were incubated at 60°C for 30 
min. Absorbance was determined at 562nm for all samples on a spectrophotometer.
Total protein concentrations were determined relative to pg of BSA standard using GB- 
Stat PPC 6.5.6 software (Dynamic Microsystems, Silver Springs, MD).
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Western Blot Analysis
In SDS-PAGE and Western blot analyses, all samples were adjusted to 2% SDS, 
loaded by equal volume and run under reducing conditions on 4-12% Bis-Tris NuPAGE 
gels with MOPS running buffer using the NuPAGE system (Invitrogen, Carlsbad, CA). 
Pre-stained Broad Range SDS Standards, (BioRad Laboratories, Hercules, CA) were 
used as markers. Gels were transferred onto a 0.45 pM nitrocellulose membrane, also 
under reducing conditions, using the NuPAGE system (Invitrogen, Carlsbad, CA).
Blots were blocked in 5% milk in PBS-0.5% Tween 20 followed by incubation in 
chicken anti-human BOG25 IgY primary antibody or chicken pre-immune IgY antibody 
(Aves Laboratories, Tigard, OR), each diluted 1:10,000 in 1% milk in PBS. The blots 
were rinsed with PBS-0.5% Tween 20, followed by incubation with anti-chicken IgY 
secondary antibody conjugated with horseradish peroxidase (Aves Laboratories, Tigard, 
OR) diluted 1:10,000 in 1% milk in PBS. Blots were rinsed with PBS-0.5% Tween 20. 
The ECL Western Kit was used for chemiluminescent detection and blots were exposed 
to Hyperfilm ECL™ (Amersham Pharmacia Biotech, Piscataway, NJ). Protein bands 
were quantitated by scanning Western blot films followed by analysis with NIH Image 
1.62 software to determine Integrated Optical Density (IOD) for each band. Data were 
graphed relative to pg total protein using DeltaGraph software (SPSS Inc, Chicago, IL) or 
GB Stat PPC 6.5.6 software (Dynamic Microsystems, Silver Springs, MD).
Subcellular Fractionation
Nuclear (NF) and postnuclear fractions (PNF) were obtained using the NE-PER 
nuclear and cytoplasmic extraction kit (Pierce, Rockford, IL). Cells were trypsinized 
with 0.25% trypsin-EDTA (Invitrogen, Carlsbad, CA) until rounded, resuspended in
20
DMEM-F12 supplemented with 10% fetal bovine serum (FBS) and centrifuged at 800 
rpm for 10 min at 4 C. Cells were resuspended in DMEM-F12 without phenol red, 4 x 
106 cells were aliquotted, re-centrifuged at 800 rpm for 10 min at 4 C, and resuspended in 
192pl CERI plus protease inhibitors followed by incubation on ice for 10 min. 11 pi of 
CERII was added followed by vortexing and incubation on ice for 1 min. Samples were 
re-vortexed and centrifuged at 2000 g for 10 min at 4°C. The supernatant, containing the 
PNF, was then re-centrifuged twice. Likewise, the nuclei pellet was washed twice in 
96pl CER I with protease inhibitors plus 5.5pl CER II, followed by resuspension in 96pl 
NER with protease inhibitors and vortexing 15 sec every 10 min over 40 min. The nuclei 
were then centrifuged at 16,000 g for 10 min at 4=C. All samples were desalted using 
protein desalting spin columns (Pierce, Rockford, IL) and adjusted to 2% SDS before 
being analyzed by Western blot.
RNA Isolation
Total RNA was isolated from cells grown in monolayer cultures using TRI 
reagent (Molecular Research Center, Inc, Cincinnati, OH). Cells were lysed with TRI 
reagent, and incubated at 25 C for 5 min. l-bromo-3-chloropropane was added to TRI 
reagent samples, vigorously mixed for 15 sec, incubated at 25°C for 15 min, and 
centrifuged 12,000 g for 15 min at 4 C. The aqueous phase was collected, 1/2 TRI 
reagent volume of isopropanol was added, mixed, incubated at 25°C for 10 min and then 
incubated at -20 C for a minimum of 16 hours. Samples were centrifuged at 12,000 g for 
8 min at 4 C. The pellet containing total RNA was washed twice with 75% ethanol and 
centrifuged at 7500 g for 5 min at 4 C. RNA was solubilized in 600pl MilliQ water/T-75 
flask, or 90pl MilliQ water/T-25 flask and stored at -80°C.
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RNA Primers
Specific primers for BOG25, 7a5, and glyceraldehyde-3-phosphate
dehydrogenase (G3PDH) were designed using MacVector 6.5.3 Software (Accelrys Inc,
San Diego, CA) and synthesized at MWG Biotech Corp. (High Point, NC) (Table 1).
Primers were reconstituted in MilliQ water and stored at -20°C.
Table 1: Primers for RT-PCR. Table 1 displays primer sequences for BOG25, 7a5 and 
G3PDH, and expected amplification size.
PRIMER PRIMER SEQUENCE PRODUCT SIZE
Forward = top Reverse = bottom (bp)
BOG2 5 5 ' -TTCCTCACGTACATCTATGCCTC-3' 
5 ' -ATCTGCTGCTTGGAGACCTTGG-3'
370
7 a5  N-Term 5 ' -CCCATTTTTGGATGACATAACTCA-3' 
5 ' -GGGCATGTGCTGTGTCGTCTA-3 '
2 36
7 a5  C-Term 5 ' -TAGCTGATGTCCTGGGTTACTCAC-3'  
5 ' -ATCTCCAGTGTTTCCTCGATGA-3'
335
7 a5  Mid 5 ' -TGATTTTTGTGTTCAAGTGGAGCC-3'  
5 ' -GCTTTTACCTTACCTCCGAG-3'
315




Reverse transcription (RT) reactions were performed under the following 
conditions: 5.0mM MgCl2; IX PCR Buffer II; 1 OmM each dATP, dTTP, dCTP, dGTP; 
l.OU/pl RNase Inhibitor; 2.5U/pl MuLV Reverse Transcriptase; 2.5 pM random hexamer 
primer; 0.75 pg total RNA or 0.3 pg for N and C termini sequencing, and 0.5 pg for
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Mid. Thermocycler conditions were 25°C, 10 min; 42 C, 20 min; denature at 99 C, 5 min 
at 1 cycle; and stored at 4°C.
Polymerase Chain Reaction
Polymerase chain reaction (PCR) conditions were; lOpl RT reaction in 50 (ul final 
volume of: 2.0mM MgCU, IX PCR Buffer II; 2.5U/100pl AmpliTaq DNA Polymerase; 
0.2mM each dATP, dTTP, dCTP, dGTP; and 2.5pM of each primer. Thermocycler 
conditions were: 95°C, 2 min; 95°C, 45 sec; 52°C, 45 sec; 72°C, 45 sec for 40 cycles for 
BOG25 and 7a5 and 35-37 cycles for G3PDH.
Agarose Gels
lOpl of each PCR reaction was mixed with Gel Loading Solution (Sigma-Aldrich, 
St. Louis, MO), and electrophoretically separated on a 1.5% agarose gel in Tris-Acetic 
Acid-EDTA (TAE) buffer. Gels were stained and destained with ethidium bromide (0.05 
pg/ml Fisher Scientific, Pittsburgh, PA). 0.5 pg each of <j>x/HAE III fragments and 
LDNA/HIND III fragments (Invitrogen, Carlsbad, CA), were used as markers. Amplified 
DNA bands were quantitated by digitally capturing images of agarose gels using an 
Ultraviolet Transilluminator, and a Kodak EDAS 290 camera with Kodak ID 3.5.3 LE 
USB software. Bands were quantitated and an IOD for each DNA band was determined 
using NIH Image 1.62 software and determining. Data were plotted as IOD of BOG25 or 
7a5 or relative to IOD of G3PDH using DeltaGraph 4.5 software (SPSS Inc, Chicago,
IL).
Subcloning and Sequencing
Subcloning of RT-PCR products was performed using the PCR-TRAP Cloning 
System (GenHunter Corp., Nashville, TN). Briefly, 5.0 or 10.0 pi of RT-PCR product
23
was subcloned into the PCR-TRAP vector at 16°C overnight followed by transformation 
into GH Competent cells. Transformed bacteria were plated onto tetracycline agar plates 
and grown overnight at 37°C. Colonies containing the correct insert were determined by 
PCR using the vector-specific Lgh and Rgh primers followed by growth in 5 ml cultures. 
Plasmid DNA purification was performed using the Wizard Plus DNA Purification 
System (Promega Corp., Madison WI) and plasmid concentration was determined using 
absorption 260/280 nm on a spectrophotometer. Sequencing of plasmid DNA was 
performed at MWG Biotech Corp. (High Point, NC) using the vector-specific Lseq and 
Rseq primers. All sequencing alignments were performed using MacVector 6.5.3 




Preliminary BOG25 and 7a5 Protein Expression 
Western Blot Analysis
The working hypothesis of this study is that the BOG25 and 7a5 proteins are 
important to the cancer phenotype, and therefore, will exhibit a substantial difference in 
expression between the cancer cell lines and/or between the cancer and normal cell lines. 
Substantial differential expression includes a much higher level of expression of a 
cancerous cell line to the normal and/or another cancerous cell line. To characterize the 
levels of BOG25 family of proteins, total cell lysates from bladder, prostate and breast 
cell lines were analyzed. Based on preliminary results, breast cell lines were chosen for 
further study with subcellular fractionation and mRNA analyses to determine if the 
BOG25 proteins had subcellular localization differences and for alterations in mRNA 
levels with respect to corresponding protein levels.
Cell lysates from a series of bladder cell lines that included immortalized normal 
urothelial cell line UROtsa, and transitional cell carcinomas HTB 1, HTB 2, HTB 5 and 
CRL-1472 were collected and analyzed by Western blot using a polyclonal BOG25 IgY 
antibody that detects both BOG25 and 7a5 (Figure 3 A). BOG25 and 7a5 proteins were 
detected at the molecular weights of 120kD, and lOOkD, respectively. Compared to the 





UROtsa HTB 1 HTB 2 HTB 5 CRL-1472
Figure 3: Western blot and analysis of BOG25 and 7a5 proteins from bladder cell lines. 
(A) Lysates from bladder normal cell line UROtsa, and cancerous cell lines HTB 1, HTB 
2, HTB 5 and CRL 1472 were immunoblotted using a chicken anti-human BOG25 
antibody. Levels of BOG25 (B) and 7a5 (C) proteins were quantitated from total cell 
lysates and are shown as IOD/pg total protein with fold level differences in comparison 
to the cell line with the lowest protein expression above each bar.
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barely detectible in this cell line. BOG25 bands in HTB 1 and HTB 5 cell lines were 
more intense than the other cell lines. Additionally, the 7a5 band appeared very intensely 
in the HTB 5 cell line compared to all the other bladder cell lines. Western blot data 
were quantitated and shown as Integrated Optical Density (IOD) per p.g total protein 
(Figure 3 B and C). Quantitation of BOG25 from the immunoblot showed that the HTB 
5 cell line expressed the highest level of BOG25, with 6.5-fold more than the CRL-1472 
cell line (Figure 3 B). In addition, HTB 5 cells expressed a very high level of 7a5 
protein, 39-fold more than HTB 2 cells (Figure 3 C). The HTB 2 cell line had a low level 
of expression of 7a5, 17- and 11-fold less than UROtsa and HTB 1 cell lines, 
respectively. Among the bladder cell lines, the 7a5 protein expressed a substantial 
difference in the most advanced cancer cell line, HTB 5.
Similarly, cell lysates from a series of prostate cell lines including an 
immortalized normal cell line RWPE, an androgen responsive adenocarcinoma LNCaP, 
and 2 androgen-independent adenocarcinomas DU-145 and PC-3 were collected and 
analyzed by Western blot analysis using the polyclonal BOG25 IgY antibody that detects 
both BOG25 and 7a5 (Figure 4 A). Examination of the immunoblot showed that the 
LNCaP cell line had the lowest band intensity for both BOG25 and 7a5 proteins.
Western blot data were quantitated and are shown as IOD per p,g total protein (Figure 4 B 
and C). BOG25 was expressed at slightly lower levels in all three of the cancerous cell 
lines, with LNCaP expressing the lowest at 2.5-fold less than the normal cell line, RWPE 
(Figure 4 B). Quantitation of 7a5 showed that LNCaP also had the lowest expression, 
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B. BOG25
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Figure 4: Western blot and analysis of BOG25 and 7a5 proteins from prostate cell lines. 
(A) Lysates from prostate normal cell line RWPE, and cancerous cell lines LNCaP, DU- 
145 and PC-3 were immunoblotted using a chicken anti-human BOG25 antibody. Levels 
of BOG25 (B) and 7a5 (C) proteins were quantitated from total cell lysates. Levels of 
BOG25 and 7a5 are shown as IOD/jig total protein with fold level differences above each 
bar.
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substantial protein expression difference was not observed with either BOG25 or 7a5 in 
the prostate cell lines.
Total cell lysates from a series of breast cell lines including an immortalized 
normal breast cell line MCF-10, cancerous estrogen receptor negative cell lines MDA 
and Hs578T, and cancerous estrogen receptor positive cell lines MCF-7 and T-47D were 
collected and analyzed by immunoblot using the BOG25 IgY antibody that detects both 
BOG25 and 7a5 (Figure 5 A). Hs578T exhibited a very intense BOG25 band that 
appeared almost as intensely as the 7a5 band. Western blot data were quantitated and 
shown as IOD per pg total protein (Figure 5 B and C). Quantitation, using an average of 
two experiments, showed that Hs578T cells had a 14-fold higher expression level of 
BOG25 than MCF-7 cells (Figure 5 B). The normal cell line MCF-10, and cancerous cell 
lines MDA, MCF-7 and T-47D expressed BOG25 at a much lower level than Hs578T 
(Figure 5 B). Quantitation of the immunoblot also showed that Hs578T expressed 7a5 at 
almost 4-fold higher than MCF-7, however, no substantial protein expression difference 
was observed with 7a5 in the breast cell lines (Figure 5 C). Among the breast cell lines, 
the BOG25 protein expressed a substantial difference in the most advanced cancer cell 
line, Hs578T.
These preliminary data show that all breast, bladder and prostate cell lines 
examined expressed both BOG25 and 7a5 proteins. However, some cancer cell lines 
such as Hs578T and HTB 5 expressed very high levels of BOG25 and 7a5, respectively, 
while other cancer cell lines such as MCF-7 and HTB 2 expressed low levels of both 
BOG25 and 7a5 (Table 2). Hs578T expressed a substantial differential of BOG25, a 
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Figure 5: Western blot and analysis of BOG25 and 7a5 proteins from breast cell lines.
(A) Cell lysates from breast normal cell line MCF-10, and cancerous cell lines MDA- 
MB-231 (MDA), Hs578T, MCF-7 and T-47D were immunoblotted using a chicken anti­
human BOG25 antibody. Levels of BOG25 (A) and 7a5 (C) proteins were quantitated 
from lysates of two separate experiments and are shown as the average from two separate 
experiments in IOD/pg total protein. Fold level differences are shown above each bar.
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Table 2: Results Summary. The ratio of the lowest expresser to highest expresser for 
BOG25 and 7a5 protein is shown for each cell culture system.
B la d d e r P ro s ta te B re a s t
HTB 2: HTB 5 LNCaP: PC-3 MCF-7: Hs578T
BOG25 1 : 7 1 : 2 1 : 14
7a5 1 : 39 1 : 6 1 : 4
results, the breast cell lines were further characterized for differences in subcellular 
distribution of the BOG25 proteins and for differences in message levels of BOG25 and 
7a5.
Subcellular Distribution and Message Levels of BOG25 and 7a5 in Breast Cell Lines
Subcellular Fractionation
The hypothesis that Hs578T cells, which express very high levels of BOG25, 
would distribute more BOG25 in either the nucleus or plasma membrane compared to the 
to the other breast cell lines was tested using subcellular fractionation. The NE-PER 
reagent protocol was used to determine the subcellular localization of BOG25 and 7a5 
proteins. Post-nuclear fractions (PNF) consisted of non-nuclear membranes and cytosol, 
and nuclear fractions (NF) contained the nuclear membrane and contents within the 
nucleus. All fractions were adjusted to 2% SDS, electrophoretically separated on a 4- 
12% Bis-Tris gel and immunoblotted with the BOG25 IgY antibody that detects both 
BOG25 and 7a5 (Figure 6 A). Subcellular fractionation was performed twice using two 
separate sets of cell cultures and results from both experiments are shown in Figure 6 (B-
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MCF-10 MDA Hs578T MCF-7 T-47D
B. BOG25 C. 7a5
D. BOG25 E. 7a5
Figure 6 : Western blot and analysis of the subcellular localization of BOG25 and 7a5 
proteins from breast cell lines. (A) Post-nuclear fractions (PNF) contain membranes and 
cytosol. Nuclear fractions (NF) contain the nuclear membrane and nuclear contents.
PNF and NF were isolated from breast normal cell line MCF-10, and cancerous cell lines 
MDA-MB-231 (MDA), Hs578T, MCF-7 and T-47D using the NE-PER reagent and 
detected with the chicken anti-human BOG25 antibody. This experiment was performed 
twice on separate sets of cell cultures. Levels of BOG25 (B and D) and 7a5 (C and E) 
proteins in PNF (black bar) and NF (grey bar) were quantitated for each experiment. 
Levels of BOG25 and 7a5 are shown as IOD/pg total protein with fold level differences 
above each bar.
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E). Although BOG25 NF bands were faint, the immunoblot showed that both BOG25and 
7a5 proteins were found in the NF and PNF in all breast cell lines. Hs578T 
expressed BOG25 at the highest intensity in both the PNF and the NF. Additionally, it 
was noted that 7a5 nuclear fractions migrated higher on the Western blot than the 
respective PNF and appeared to contain a doublet band in all breast cell lines. These 
Western blot data were quantitated and are shown as IOD per pg total protein (Figure 6 
B-E). Quantitation of BOG25 showed expression at approximately a 1:1 ratio of PNF to 
NF in all breast cell lines including Hs578T cells (Figure 6 B and D). Quantitation of the 
immunoblot also showed that the 7a5 protein was expressed at higher levels in the NF 
than PNF in all cell lines (Figure 6 C and E). No substantial alteration in subcellular 
localization was observed for either BOG25 or 7a5, and the Hs578T cell line distributed 
BOG25 and 7a5 similarly to the other breast cell lines (Figure 6 B-E).
7a5 RT-PCR, Subcloning and Sequencing 
7a5 was identified by the Human Genome Project as a putative protein similar to 
BOG25. To confirm that 7a5 mRNA was being transcribed, RT-PCR amplification of 3 
regions of the 7a5 coding region including the N-term, Mid and C-term were amplified 
from total RNA isolated from the retinal pigment epithelial cell line, ARPE-19, and from 
Hs578T breast cancer cells, followed by subcloning and DNA sequencing. 7a5-specific 
primers were selected based on the reported genomic sequence and were synthesized by 
MWG Biotech Corp. Reverse transcription reactions were performed using 0.3 pg of 
total RNA for the N-term and C-term regions, and 0.5 pg of total RNA for the Mid region 
and random hexamer primers. PCR reactions were then performed using the 7a5 specific 
primers (See Table 1 in Materials and Methods). RT-PCR products were
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electrophoretically separated on agarose gels and visualized using ultraviolet light to 
identify cDNA banding patterns (Figure 7). The 7a5 N-Term segment contains 236 base 
pairs (bp) and amplified to the predicted size (Figure 7 A, Lane 4). The 7a5 N-Term 
segment is located within exon 2 , and reverse transcriptase minus and plus conditions 
(Figure 7 A, Lanes 3 and 4 respectively) were run to determine if the amplified product 
could have been generated from the presence of contaminating genomic DNA. Since the 
236 bp-band was not seen in the minus RT- reaction (Figure 7 A, Lane 3), the PCR 
product in the RT plus reaction was most likely amplified from 7a5 mRNA. The 7a5 C- 
Term segment spans exons 2 and 3 and the correct size product would most likely be 
from cDNA and not contaminating genomic DNA. The C-Term segment contains 335 bp 
and amplified to the correct, predicted size (Figure 7 A, Lane 1). Likewise, the 7a5 Mid 
segment contains 315 bp and amplified to the predicted size (Figure 7 B, Lane 1). The 
7a5 Mid segment is also located within exon 2, and no visible band was amplified in the 
minus reverse transcriptase reaction (Figure 7 B, Lane 3). The RT-PCR 7a5 N-Term, Mid 
and C-Term products were then individually subcloned into the PCR-TRAP vector, and 
purified plasmid DNA was sequenced at MWG Biotech Corp. ARPE-19 samples 
displayed the strongest amplified products for the 7a5 segments and therefore, these 
samples were used for subcloning and sequencing. The sequence for each 7a5 segment 
was aligned to the sequence submitted by the Human Genome Project and was found to 
match the predicted coding region within the genomic sequence with 100% identity 
thereby confirming about 36% of the 7a5 open reading frame (Figure 8 A-C). The 
regions of 7a5 that have been cDNA sequenced are shown relative to the aligned amino 
acid sequence of 7a5 to an N-terminal truncated BOG25 sequence (Figure 9). The amino
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7a5 C 7a5 N
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Figure 7: RT-PCR of 3 regions of 7a5 (N-Term, Mid and C-Term) using total RNA 
isolated from ARPE-19 cells. (A) 7a5 C-Term segment is seen in lane 1, and 7a5 N- 
Term in lane 4. Reverse transcriptase minus and plus conditions for N-terminus are in 
lanes 3 and 4, respectively. (B) Reverse transcriptase enzyme plus and minus conditions 
for 7a5 Mid segment are shown in lanes 1 and 3 respectively. The Molecular weight 
markers (|)x/HAE III and ADNA/HIND III were run in lane 2 (A and B).
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7 a 5  C te rm 3 TAGCTGATGT CCTGGGTTAC TCACATCTGT CCCTGGAAGA TTTTGATCAA ATTCAAGCAG ACAAAGAATC AGAGAAAGTT
ATCGACTACA GGACCCAATG AGTGTAGACA GGGACCTTCT AAAACTAGTT TAAGTTCGTC TGTTTCTTAG TCTCTTTCAA
1 .  7 a 5  cDNA 1 9 0 0 1 9 1 0 1 9 2 0 1 9 3 0 1 9 4 0 1 9 5 0 1 9 6 0 1 9 7 0
[ 1 3 4 0  ] TAGCTGATGT CCTGGGTTAC TCACATCTGT CCCTGGAAGA TTTTGATCAA ATTCAAGCAG ACAAAGAATC AGAGAAAGTT>
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 1 1 1 1 1 1 1 1 I I
7 a 5  C te rm 3 TAGCTGATGT CCTGGGTTAC TCACATCTGT CCCTGGAAGA TTTTGATCAA ATTCAAGCAG ACAAAGAATC AGAGAAAGTT
90 1 0 0 1 1 0 1 2 0 1 3 0 140 1 5 0 1 6 0
* * * * ★ * * *
7 a 5  C te rm 3 TCTTATGTTA TAAAGAAGTT AAAGGAAGAT TGCCACACAG AGAGAAATAC AAGGAAGTTT CTGTATGAAC TTATTGTGGC
AGAATACAAT ATTTCTTCAA TTTCCTTCTA ACGGTGTGTC TCTCTTTATG TTCCTTCAAA GACATACTTG AATAACACCG
1 .  7 a 5  cDNA 1 9 8 0 1 9 9 0 2 0 0 0 2 0 1 0 2 0 2 0 2 0 3 0 2 0 4 0 2 0 5 0
[ 1 3 4 0  ] TCTTATGTTA TAAAGAAGTT AAAGGAAGAT TGCCACACAG AGAGAAATAC AAGGAAGTTT CTGTATGAAC TTATTGTGGC>
l l l l l l l l l l 1 1 1 1 1 I I  1 1 1 l l l l l l l l l l l l l l l l l l l l 1 1 1 1 1 1 1 1 I I l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
7 a 5  C te rm 3 TCTTATGTTA TAAAGAAGTT AAAGGAAGAT TGCCACACAG AGAGAAATAC AAGGAAGTTT CTGTATGAAC TTATTGTGGC
1 7 0 1 8 0 1 9 0 2 0 0 2 1 0 2 2 0 2 3 0 2 4 0
* ★ * * * * * *
7 a 5  C te rm 3 TCTTCTGAAA ATGGATTGCC AAGAGTTAGT CGCACGT CT C ATCCAAGAAG CTGCTGTTCT GACTTCAGCT GTCAAGCTTG
AGAAGACTTT TACCTAACGG TTCTCAATCA GCGTGCAGAG TAGGTTCTTC GACGACAAGA CTGAAGTCGA CAGTTCGAAC
1 .  7 a 5  cDNA 2 0 6 0 2 0 7 0 2 0 8 0 2 0 9 0 2 1 0 0 2 1 1 0 2 1 2 0 2 1 3 0
[ 1 3 4 0  ] TCTTCTGAAA ATGGATTGCC AAGAGTTAGT CGCACGTCTC ATCCAAGAAG CTGCTGTTCT GACTTCAGCT GTCAAGCTTG>
l l l l l l l l l l 1 1 1 1 I I  1 I I  1 l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
7 a 5  C te rm 3 TCTTCTGAAA ATGGATTGCC AAGAGTTAGT CGCACGTCTC ATCCAAGAAG CTGCTGTTCT GACTTCAGCT GTCAAGCTTG
2 5 0 2 6 0 2 7 0 2 8 0 2 9 0 3 0 0 3 1 0 3 2 0
■* * * * * * * *
7 a 5  C te rm 3 GAAAAGGCTG GAGGGAACTA GCTGAAAAGT TAGTACGACT CACAAAGCAA CAAATGGAGG CATATGAAAT TCCTCATCGA
CTTTTCCGAC CTCCCTTGAT CGACTTTTCA ATCATGCTGA GTGTTTCGTT GTTTACCTCC GTATACTTTA AGGAGTAGCT
1 .  7 a 5  cDNA 2 1 4 0 2 1 5 0 2 1 6 0 2 1 7 0 2 1 8 0 2 1 9 0 2 2 0 0 2 2 1 0
[ 1 3 4 0  ] GAAAAGGCTG GAGGGAACTA GCTGAAAAGT TAGTACGACT CACAAAGCAA CAAATGGAGG CATATGAAAT TCCTCATCGA>
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
7 a 5  C te rm 3 GAAAAGGCTG GAGGGAACTA GCTGAAAAGT TAGTACGACT CACAAAGCAA CAAATGGAGG CATATGAAAT TCCTCATCGA





1 .  7 a 5  cDNA 2 2 2 0
[ 1 3 4 0  ] GGAAACACTG GAGAT>
l l l l l l l l l l M i l l
7 a 5  C te rm 3 GGAAACACTG GAGAT
Figure 8 : 7a5 cDNA alignment. 7a5 N-Term (A), Mid (B) and C-Term (C) clones were 
sequenced and aligned to the predicted coding region of the 7a5 gene. The subcloned 
cDNA sequences matched the 7a5 gene sequence with 100% alignment. The top two 
rows show the double strand base pairing of the subcloned sequences. Below, the 
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Figure 9: 7a5 homology to BOG25. The 7a5 amino acid sequence (top) exhibits 60% 
similarity and identity (gray boxed regions) to the truncated (A) BOG25 amino acid 
sequence (bottom). The last 2.5 rows contain the death domain and have an even higher 
amino acid homology. The N-terminus including the SH3 domain of BOG25 is not 
shown. The sequenced 7a5 N-Term, 7a5 Mid-sequence and 7a5 C-Term segments are 
shown with a black bar above each region.
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acid sequence of 7a5 aligns to BOG25 amino acid sequence with 60% similarity and 
identity (Figure 9, gray boxed regions). The death domain is located on the last 2.5 lines 
with an even higher homology of 7a5 to BOG25 (Figure 9).
mRNA and Corresponding Protein Levels o f BOG25 and 7a5 In Breast Cell Lines 
The hypothesis that breast cells would exhibit similar mRNA and corresponding 
protein levels of BOG25 and 7a5 was tested by comparing triplicate mRNA samples, and 
triplicate protein samples. Six flasks were used to generate triplicate total RNA and total 
cell lysates. TRI reagent was used to isolate total RNA from cells grown in monolayer 
cultures and 2% SDS buffer was used to obtain cell lysates from corresponding cultures. 
BOG25, 7a5 and glyceraldehyde-3-phosphate dehydrogenase (G3PDH) message levels 
were amplified by RT-PCR and electrophoretically separated on 1.5% agarose gels 
(Figure 10 A-C). Reverse transcription amplification was performed using 0.75 p.g total 
RNA and random hexamers, followed by 7a5 N-Term, BOG25 and G3PDH specific 
primers (See Table 1 in Materials and Methods). Since the 7a5 N-Term amplification 
was consistently detected as a high intensity band compared to the C-Term and Mid 
reactions, the N-term primer set was chosen for 7a5 amplification. G3PDH, a 
constitutively active gene, was used as a control. G3PDH spans multiple exons and 
therefore, should not amplify a 283 bp band if amplified from contaminating genomic 
DNA. The BOG25 primer set spans exons 4-5 while the 7a5 primer set is within exon 2. 
Therefore, a minus RT- reaction was run as a control to determine if the amplified 
products could have been generated from contaminating genomic DNA (Figure 10 D). 
Since no bands were seen in the minus RT reaction, the PCR products for G3PDH, 
BOG25 and 7a5 most likely did not originate from contaminating genomic DNA.
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A. Flask 1
1 2 3 4  5 6  7  8  9  10  1 1 1 2 1 3  1 4 1 5 1 6
900  bp
283 bp
370  bp 
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3 4 5 6 7 8 9 10 11 12 13 14 15 16
G3PDH I BOG25 I 7a5
Figure 10: RT-PCR of G3PDH, BOG25 and 7a5. G3PDH, BOG25 and 7a5 were 
amplified from each breast cell lines in triplicate (A-C) using RT-PCR. Breast cell lines 
included: normal MCF-10 (Lanes 6 , 11, 16), and cancerous MDA (Lanes 5,10,15), 
FIs578T (Lanes 4, 9, 14), MCF-7 (Lanes 3, 8 , 13) and T-47D (Lanes 2, 7, 12). Lane 1 
contains (fix/HAE III and XDNA/HIND III molecular marker. Reverse transcriptase 
minus reaction for Flask 1 RNA preparations are shown in (D).
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Additionally, the optimum cycles for the control, G3PDH, were determined to be 35- 
37cycles, and the cycles for BOG25 and 7a5 were optimum at 40 cycles each. In order to 
compare mRNA levels to protein levels, cell lysates from corresponding triplicate protein 
preparations were collected and analyzed by Western blot using the polyclonal BOG25 
IgY antibody that detects both BOG25 and 7a5 (Figure 11).
Correct size bands were always detected for the G3PDH control in all cell lines 
(Figure 10). Band intensities showed subtle differences among cell lines. Bands on the 
agarose gels were quantitated and are shown as IOD (Figure 12 A-C). Only subtle 
differences were seen among the cell lines in all 3 flasks. G3PDH data were normalized, 
averaged and shown as IOD in Figure 12 D. The averaged data of G3PDH showed only 
very subtle differences between the cell lines and triplicate flasks.
BOG25 RT-PCR resulted in a 370 bp band from all 3 Hs578T samples, and 
BOG25 was amplified from MDA samples in two out of three flasks. The other cell lines 
never amplified a detectable BOG25 370 bp band. BOG25 bands on the agarose gels 
were quantitated and shown as IOD (Figure 13 A-C). The 3 samples of Hs578T 
expressed a high level of BOG25 message, whereas the two samples of MDA expressed a 
moderate level of BOG25 message, compared to the cell lines MCF-10, MCF-7 and T- 
47D. Triplicate BOG25 mRNA data were normalized, averaged and shown as IOD 
(Figure 14 A). Measurements for MCF-10, MCF-7 and T-47D reflect background as 
there were no visible bands for these cell lines. Data are reported as averages from the 
individual flasks. The average BOG25 mRNA level for Hs578T was very high, and the 
level for MDA was moderate, compared to the cell lines MCF-10, MCF-7 and T-47D. 




MCF-10 MDA Hs578T MCF-7 T-47D
B. Flask 2
-120  kD
MCF-10 MDA Hs578T MCF-7 T-47D
C. Flask 3
MCF-10 MDA Hs578T MCF-7 T-47D
Figure 11: Western blots of BOG25 and 7a5 proteins from total cell lysates. Cell lysates 
in normal breast cell line MCF-10, and cancerous breast cell lines MDA-MB-231 
(MDA), Hs578T, MCF-7 and T-47D were immunoblotted in triplicate (A-C) using a 
1:10,000 dilution of chicken anti-human BOG25 antibody.
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MCF-10 MDA Hs578T MCF-7 T-47D
B. G3PDH mRNA Flask 2
80 1.9
MCF-10 MDA HS578T MCF-7 T-47D
C. G3PDH mRNA Flask 3
80
70
MCF-10 MDA HS578T MCF-7 T-47D
D. G3PDH mRNA Average
1 1.5 1 5
0.9
0 .7  1.0
MCF-10 MDA HS578T MCF-7 T-47D
Figure 12: mRNA analysis of G3PDH. RT-PCR was used to determine levels of G3PDH 
mRNA from triplicate total RNA preparations from breast cell lines: normal cell line 
MCF-10, and cancerous cell lines MDA-MB-231 (MDA), Hs578T, MCF-7 and T-47D. 
Levels of G3PDH are shown as IOD (A-C). Triplicate G3PDH data were normalized, 
averaged and graphed as IOD (D). Fold level differences are shown above each bar.
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B. BOG25 mRNA Flask 2 E. BOG25 Protein Flask 2
C. BOG25 mRNA Flask 3 F. BOG25 Protein Flask 3
Figure 13: mRNA and protein analysis of BOG25. RT-PCR was used to determine levels 
of BOG25 mRNA from triplicate total RNA preparations from breast cell lines: normal 
cell line MCF-10, and cancerous cell lines MDA-MB-231 (MDA), Hs578T, MCF-7 and 
T-47D. Levels of BOG25 mRNA are shown as IOD (A-C). Corresponding triplicate 
flasks of BOG25 protein (D-F) were quantitated from lysates of breast cell lines and are 
shown as IOD/pg total protein. Fold level differences are shown above each bar.
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A. BOG25 mRNA Average B. BOG25/G3PDH mRNA
C. BOG25 Protein Average
9  1 0 9
MCF-10 MDA Hs578T MCF-7 T-47D
Figure 14: BOG25 average mRNA and protein analyses. BOG25 mRNA (A) and protein 
(B) were reported as the average from 3 individual flasks. Averaged BOG25 (C) mRNA 
are shown relative to G3PDH. mRNA levels are shown as IOD and protein levels are 
shown as IOD/pg total protein. Fold differences are shown above each bar.
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active G3PDH, the BOG25 mRNA level was very high in Hs578T compared to all the 
other cell lines (Figure 14 B).
Corresponding immunoblots revealed that a 120 lcD BOG25 band was expressed 
by all cell lines (Figure 11). However, compared to the other breast cell lines, BOG25 
protein expression was highest in Hs578T cells. BOG25 Western blot data were 
quantitated and are shown as IOD per p,g total protein (Figure 13 D-F). BOG25 protein 
levels in the breast cell lines were similar quantitatively to the mRNA levels from the 
corresponding cell line. Hs578T expressed a much higher level of both BOG25 protein 
and mRNA than all other cell lines. Triplicate BOG25 protein data were normalized, 
averaged and shown as IOD per fig total protein (Figure 14 C). The average BOG25 
protein level for Hs578T was much higher than all other cell lines, similar to mRNA 
levels where all other cell lines expressed BOG25 at a lower level than Hs578T.
7a5 RT-PCR resulted in a 236 bp band that amplified correctly to the expected 
size in MCF-10, Hs578T, MCF-7, and T-47D cell lines. The correctly-sized 7a5 band 
was detected only once in MDA, where the other two flasks revealed a faint band at 
about 900 bp that could not be subcloned or re-amplified (Figure 10 A and C). Only the 
236 bp band for the MDA cell line was quantitated. 7a5 bands on the agarose gels were 
quantitated and shown as IOD (Figure 15 A-C). The 7a5 mRNA level in the MDA cell 
line was lowest compared to all other cell lines, which expressed similar 7a5 mRNA 
levels. Triplicate 7a5 mRNA data were normalized, averaged and shown as IOD (Figure 
16 A). The averaged 7a5 level in the MDA cell line appeared substantial, but the level 
difference was due to the inability to amplify a 236 bp product from the 7a5 message in 2 
of the 3 samples. Averaged 7a5 mRNA levels were similar to the levels in individual
46
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MCF-10 MDA Hs578T MCF-7 T-47D MCF-10 MDA HS578T MCF-7 T-47D
Figure 15: mRNA and protein analysis of 7a5. RT-PCR was used to determine levels of 
7a5 mRNA from triplicate total RNA preparations from breast cell lines: normal cell line 
MCF-10, and cancerous cell lines MDA-MB-231 (MDA), Hs578T, MCF-7 and T-47D. 
Levels of 7a5 mRNA are shown as IOD (A-C). Corresponding triplicate flasks of 7a5 
protein (D-F) were quantitated from lysates of breast cell lines and are shown as lOD/pg 
total protein. Fold level differences are shown above each bar.
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A. 7a5 mRNA Average B. 7a5/G3PDH mRNA




M CF-10 MDA H s5 78T  M CF-7 T-47D
Figure 16: 7a5 average mRNA and protein analyses. 7a5 mRNA (A) and protein (B) 
were reported as the average from 3 individual flasks. Averaged 7a5 (C) mRNA are 
shown relative to G3PDH. mRNA levels are shown as IOD and protein levels are shown 
as IOD/pg total protein. Fold differences are shown above each bar.
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samples where 7a5 was shown to be lowest in MDA, in contrast to the other cell lines, 
which showed similar levels of 7a5 mRNA. When averaged 7a5 mRNA data is shown 
relative to the constitutively active G3PDH, only minor differences were seen among 
MCF-10, Hs578T, T-47D and MCF-7 (Figure 16 B).
Corresponding immunoblots revealed that a lOOkD 7a5 band was expressed by all 
cell lines (Figure 11). All cell lines showed similar 7a5 band intensities on the 
immunoblot. 7a5 triplicate protein Western blot data were quantitated and are shown as 
IOD per pg total protein (Figure 15 D-F). The individual flask data of 7a5 showed only 
subtle differences among cell lines. Triplicate 7a5 protein data were normalized, 
averaged and shown as IOD per pg total protein (Figure 16 C). Averaged 7a5 protein 
data showed subtle differences among cell lines and were similar to mRNA levels except 
that protein and message levels did not correlate within the MDA cell line, where RT- 




The hypothesis of this study is that the BOG25 and 7a5 proteins are important to 
the cancer phenotype, and therefore, will have a substantial difference in expression 
between the cancer cell lines and/or between the cancer and normal cell lines. Moreover, 
with such differences in expression one would expect to observe changes in subcellular 
localization and message levels reflective of levels in protein expression. BOG25 and 
7a5 expression has never been examined in cancer. To characterize the levels of BOG25 
family of proteins, total cell lysates from bladder, prostate and breast cell lines were 
analyzed. Breast cell lines were further characterized by subcellular fractionation to 
determine subcellular localization differences of BOG25 and 7a5, and RT-PCR was 
employed to investigate alterations in mRNA levels of BOG25 and 7a5 with respect to 
total protein levels.
Bladder cell lines did not show a substantial difference in BOG25 protein 
expression. However, a substantial 7a5 protein expression among the cancer cell lines 
was observed with a 39-fold increase in 7a5 in HTB 5 cells compared to HTB 2 cells. 
Since HTB 5 cells are from an invasive, high-grade metastatic transitional cell carcinoma, 
7a5 protein expression in this type of bladder cancer cell line indicated a correlation with 
advancement in cancer stage.
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Prostate cell lines expressed only subtle differences in BOG25 levels among all 
the cell lines. 7a5 protein expression in prostate cell lines also showed only slight 
differences between the cell lines. No substantial differences of either BOG25 or 7a5 
were seen between normal and cancerous cell lines or between cancerous cell lines.
Averaged and normalized data for BOG25 expression in breast studies revealed a 
14-fold increased expression in one cell line, Hs578T. The other cell lines, including 
normal MCF-10 cells, expressed BOG25 at a very low level compared to Hs578T. 7a5 
protein expression showed only slight differences in levels among all the breast cell lines. 
Subcellular fractionation was performed to determine if the Hs578T cells, which express 
very high levels of BOG25, would distribute more BOG25 or 7a5 to either the nucleus or 
plasma membrane compared to other breast cell lines. Pro-apoptotic proteins bind and 
aggregate with each other, translocate to specific subcellular locations and proteolytically 
cleave key proteins to induce cell death. For example, the pro-apoptotic protein Bid is 
normally located in the cytosol, and when cleaved by caspase-8, it associates with the 
mitochondrial membrane to facilitate the release of cytochrome c (Reed, 2000). Upon 
release, cytochrome c translocates to the cytoplasm and aggregates with Apaf-1 to form 
the apoptosome and activate caspase-9 (Zou et al., 1999). A mutated nuclear export 
signal in FADD has shown to reduce apoptosis (Gomez-Angelats and Cidlowski, 2003), 
indicating that FADD normally resides in the nucleus and translocates to the plasma 
membrane when the extrinsic pathway is engaged. If BOG25 and 7a5 were active in 
death receptor apoptosis, one would expect that the BOG25 proteins may translocate 
between their subcellular localizations. The NE-PER reagent protocol was used to 
determine the subcellular localization of BOG25 and 7a5 proteins. Examination of the
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results revealed a 1:1 ratio of BOG25 in the PNF and NF in the Hs578T cell line on two 
separate sets of cell cultures. 7a5 was found to be higher in the NF than the PNF in all 
breast cell lines, however, there was no substantial differential localization to, and 
expression in, the Hs578T cell line. Interestingly, the nuclear fractions of 7a5 contained 
a doublet band and both bands migrated slightly higher than lOOkD 7a5 in the PNFs.
One possibility is that nuclear 7a5 is phosphorylated as there are 3 tyrosine 
phosphorylation sites identified in 7a5.
No substantial differential expression of BOG25 or 7a5 was shown between 
fractions and no substantial differential localization was found in either fraction for 
Hs578T. Subcellular fractionation studies performed on RPE and COS-7 cells by 
Khanobdee et al. (2004 submitted) demonstrated that BOG25 and 7a5 localized to the 
nuclear fraction and postnuclear fraction in approximately a 3:1 ratio which is a similar 
distribution to that found in breast cells. In addition, BOG25 was determined to localize 
to the plasma membrane and nuclear periphery in confocal microscopy studies using 
BOG25 fusion proteins expressed from the pEGFP and c-myc tagged pCMV-Tag3 
vectors (Khanobdee et al., 2003 Abs and Koppelman et al., 2003 Abs). Overall, these 
studies indicate that neither BOG25 or 7a5 preferentially localize to the nucleus or 
cytosolic membranes/plasma membrane in normal compared to cancerous cells, and the 
distribution of BOG25 and 7a5 is similar to cell lines not related to breast. If BOG25 or 
7a5 localization were important for tumorigenicity, then BOG25 or 7a5 would have 
shown a differential localization within the Hs578T cells to avoid apoptosis through 
death receptor signaling.
Triplet RT-PCR studies used to determine the regulation level of BOG25 in breast
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cell lines revealed a strong BOG25 band in all three samples of Hs578T. Two samples 
showed the BOG25 band in MDA cell lines while no other cell lines expressed the 
BOG25 band in all 3 samples. The averaged BOG25 mRNA level for Hs578T was very 
high, and the level for MDA was moderate, compared to the cell lines MCF-10, MCF-7 
and T-47D. Corresponding triplicate protein samples of breast cell lines reflected the 
triplicate mRNA levels where all cell lines showed BOG25 protein expression at a much 
lower level than Hs578T. This indicates that there is a possibility of a transcriptional 
regulation of BOG25 levels. Triplet RT-PCR studies revealed the correctly sized 7a5 
band was detected in all samples, except only once in MDA, where the other two samples 
showed a faint band at about 900 bp that could not be subcloned or re-amplified. The 
averaged 7a5 mRNA level in the MDA cell line appeared substantially low, but the level 
difference is due to the inability to amplify that region of the 7a5 message in 2 of the 3 
samples. Averaged 7a5 mRNA levels were lowest in MDA, in contrast to the other cell 
lines, which showed comparable levels of 7a5 mRNA. Averaged 7a5 protein data also 
showed subtle differences among cell lines and were comparable to mRNA levels except 
that protein and message levels did not correlate within the MDA cell line. These results 
indicate a steady state level of 7a5 mRNA that correlates to 7a5 protein levels.
The highest BOG25 level in both mRNA and protein was expressed in Hs578T, 
which is the rarest form of breast cancer cell line utilized in this study. Hs578T is a 
carcinosarcoma, a rare metastatic breast cancer originating in the mammary ducts and the 
surrounding connective tissue (Hackett eta l., 1977; Goodman, 2003; Burdall etal., 
2003). In the bladder cell lines, 7a5 exhibited a very strong correlation between 7a5 
protein expression and the increase in stage of bladder transitional cell carcinomas.
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Preliminary studies revealed the highest level of 7a5 was expressed in the most advanced 
cancerous bladder cell line used in this study, HTB 5 (stage T4) (Masters et al., 1986).
HTB 5 cells are derived from an invasive and high-grade metastatic transitional cell 
carcinoma. Expression was next highest in the invasive (stage T 3) HTB 1 cell line, 
followed by the invasive (stage T2) CRL-1472 cell line and the low-grade and stage 
(stage T2) bladder cancer cell line HTB 2 was lowest in expression (Masters et al., 1986). 
The high BOG25 protein and mRNA level seen in a rare metastatic breast cancer, and the 
strong evidence from preliminary data of 7a5 protein expression following stage 
advancement in bladder cancer indicate that BOG25 and 7a5 may be excellent candidates 
as breast and bladder cancer prognostic markers, respectively.
Prognosis is the prediction of a probable course or outcome of a disease and in 
cancer is influenced by cancer stage, grade and type (Goodman and Kelly Snyder, 2003). 
Protein markers are used in determining differential localization of proteins within cells 
and changes in expression of specific proteins help to predict recurrence of disease 
(Sidransky, 2002). An excellent prognostic marker, Metallothionein 3 (MT-3), has been 
shown to be associated with ductal carcinoma in situ in tumors of patients having a poor 
outcome (Sens et al., 2001). Also, MT-3 has been analyzed in breast cell lines and was 
found to inhibit growth when overexpressed in two cell lines, supporting a possible role 
for MT-3 as a prognostic marker in breast cancer (Gurel et al., 2003).
Markers of both the death domain and EH-Network families have been examined 
for roles as cancer prognostic markers, although none are as well defined as MT-3. The 
death-domain protein Fas, the receptor for Fas-Ligand, has been analyzed as a possible 
prognostic marker in breast cancer (Mottolese et a l, 2000). This study found that 75% of
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lymph node-negative breast cancer patients expressed Fas, almost 40% of metastatic­
positive patients did not display the receptor, and Fas decreased statistically significantly 
as tumor size increased, suggesting that Fas down-regulation could be associated with 
poorer clinical outcomes. Another study analyzed Fas in bladder cancer cell lines and 
showed that despite a correlation with tumor stage that was highly significant, it was not 
related to grade or lymph node status (Maas et a l, 2004). Therefore, the overall 
conclusion was that Fas was not a good independent prognostic marker in bladder cancer. 
The association of BOG25 in the rare metastatic breast cancer, and 7a5 with transitional 
cell carcinoma advancement in stage is exciting, but as seen with Fas in bladder cancer, 
further studies are needed to statistically associate BOG25 or 7a5 with particular tumors 
or with tumor progression. Methylation of another apoptosis protein containing a C- 
terminal death domain that is also a tumor suppressor, DAP kinase, has been implicated 
in many cancers such as head and neck cancers (Bialik and Kimchi, 2004 In Press).
EH-Network proteins have also been examined as cancer markers. The Epsl5 
gene is down-regulated in breast cancer patients with short survival expectancy 
(Amatschek et al., 2004). Epsl5  has also been involved in translocations in acute 
lymphoblastic and myeloid leukemias and deletions in neuroblastomas (Salcini etal., 
1999). Overexpression of the EGFR substrate Epsl 5 in the presence of EGF, has 
transformed NIH 3T3 fibroblast cells and allowed them to grow in soft agar (Fazioli et 
al., 1993). The EGFR plays an important role in neoplastic cell proliferation and 
metastatic spread (Dancey, 2004) and requires recruitment by coated pits (Di Fiore and 
Gill, 1999). The most frequent abnormality in the EGFR in cancers is overexpression 
and not mutations within the receptor itself (Dancey, 2004). Another EH-Network
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protein that is a nonneuronal form of API 80, CALM, is involved in leukemia gene 
rearrangement (Santolini et al., 1999). Since no single gene or gene product has been 
demonstrated to be, by itself, responsible for tumor progression, changes in profiles of 
expression of multiple cellular proteins that may be relevant to patient prognosis would 
be critical in advancing the field of cancer biology and treatment.
BOG25 and 7a5 comprise a family of hybrid proteins that contain both 
endocytosis and apoptosis domains of the EH-Network and death domain families, 
respectively. This is the first study to examine the expression of BOG25 and 7a5 in 
cancer. In addition, this study is the first to confirm that mRNA for 7a5, the putative 
protein identified as similar to BOG25, is being transcribed in breast cell lines. In 
summary, this study showed that BOG25 and 7a5 proteins were expressed at a very high 
level in the Hs578T breast cell line and the HTB 5 bladder cell line, respectively, in 
comparison to normal and other cancerous cells. There is a possible transcription 
regulation of BOG25 in breast cell lines as mRNA corresponded to protein. Since the 
BOG25 proteins belong to both EH-Network and death domain families, monitoring the 
role of their expression during tumor progression may identify BOG25 or 7a5 as 
prognostic markers in breast and bladder cancers, respectively.
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